Idecabtagene Vicleucel
Research aims to address clinical challenges of triple-class refractory multiple myeloma
Novel therapies and treatment strategies could help to address the clinical challenges of triple-class refractory multiple myeloma, according to a speaker at Chemotherapy Foundation Symposium.
BCMA-directed CAR-T still shows deep, durable response in heavily pretreated myeloma
Report: CAR-T for multiple myeloma clinically beneficial, but value low at current cost
An independent panel unanimously agreed that chimeric antigen receptor T-cell therapy provides clinical benefit superior to the current standard of care for patients with relapsed or refractory multiple myeloma.
CAR T-cell therapy, bispecific T-cell engagers, other exciting treatments in multiple myeloma
Maung Myo Htut, MD, associate clinical professor in the division of multiple myeloma within the department of hematology and hematopietic cell transplantation at City of Hope, discussed treatment developments in multiple myeloma, including exciting data from ASH 2020, the role of CAR T-cell therapy, autologous hematopoietic stem cell transplant, consolidation therapy and more.
First FDA-approved CAR T-cell therapy for multiple myeloma hailed as ‘game changer’
Although it took a bit longer than expected, the first FDA approval of a chimeric antigen receptor T-cell therapy for advanced multiple myeloma will have a major impact on clinical practice, according to experts.
FDA approves Abecma, first CAR T-cell therapy for multiple myeloma
The FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory multiple myeloma.
CAR-T equally safe, effective for older patients with advanced multiple myeloma
Complete responses to idecabtagene vicleucel appeared consistent regardless of age among patients with relapsed or refractory multiple myeloma, according to study results presented at TCT Meetings Digital Experience.
Top in hem/onc: T-cell therapy, multiple myeloma treatment
The FDA has cleared an investigational new drug application for T-cell therapy to treat high-risk patients with COVID-19. It was the top story in hematology/oncology last week.
Institute issues draft scoping plan for review of anti-BCMA therapies for multiple myeloma
The Institute for Clinical and Economic Review has completed a draft scoping document for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.
FDA grants priority review to idecabtagene vicleucel for advanced multiple myeloma
The FDA granted priority review to idecabtagene vicleucel for the treatment of certain adults with relapsed or refractory multiple myeloma, according to the agent’s developers.